Copyright ©The Author(s) 2019.
World J Diabetes. Aug 15, 2019; 10(8): 446-453
Published online Aug 15, 2019. doi: 10.4239/wjd.v10.i8.446
Table 1 Glucagon-like peptide-1 receptor agonist
DrugAdministrationPhase 3 clinical trial
ExenatideTwice daily (5 µg or 10 µg)Amigo
LiraglutideDaily (0.6 mg or 0.8 mg or 1.2 mg)Leader
Exenatide ERWeekly (2 mg)Duration
LixisenatideDaily (10 µg or 20 µg)Getgoal
DulaglutideWeekly (0.75 mg or 1.5 mg)Award
SemaglutideWeekly (0.5 mg or 1.5 mg)Sustain
AlbiglutideWeekly (30 mg or 50 mg)Harmony
Table 2 Cardiovascular effect of glucagon like peptide-1 receptor agonists
Anti-atherosclerotic effectDecrease matrix metalloproteinase 2; decrease vascular smooth muscle cell proliferation
Improves endothelial functionIncrease nitric oxide-induced vasodilation; decrease oxidative stress
Anti-inflammatory effectSuppress human macrophagesby inhibition of protein kinase C
Decrease infarct/injury sizeDecrease glucose-induced apoptosis; decrease intracellular calcium overload
Modifies risk factorsImprove glycemic control; decrease body weight; decrease blood pressure; decrease low-density lipoprotein